ClinicalTrials.gg
CompletedNCT04505826Updated May 11, 2026Results posted

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

A Phase 1/2 interventional study of OP-1250 in Hormone Receptor Positive Breast Carcinoma and HER2-negative Breast Cancer, sponsored by Olema Pharmaceuticals, Inc.. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Olema Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
153
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, her2-negative breast cancer.

Read the detailed description

This is a Phase I dose escalation and dose expansion and Phase II monotherapy open--label, first--in--human study to determine the dose limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), to characterize the safety and pharmacokinetic (PK) profile, and to estimate the preliminary anti-tumor activity of OP-1250 as a single agent in adult subjects with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic or locally advanced breast cancer. This study comprises 2 Phases: Phase I (Part A [Dose Escalation] and Part B [Dose Expansion]) and Phase II. Patients must have received at least 1 prior hormonal regimen and at least 6 months of a prior continuous endocrine therapy for locally advanced or metastatic disease. Patients will be evaluated for treatment emergent adverse events (AEs) during study participation, and toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 5.0.

02

Conditions studied

  • Hormone Receptor Positive Breast Carcinoma
  • HER2-negative Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 153 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Olema Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (ECOG) performance status of 0 or 1
  • Must have received at least 1 prior hormonal regimen and at least 6 months of a prior continuous endocrine therapy for locally advanced or disease
  • Must not have received prior oral endocrine therapy \< 2 weeks prior to first dose
  • Must not have received prior, chemotherapy in 2 weeks or within 5 half-lives whichever is earlier, antibody therapy within 4 weeks or therapy within 4 weeks or 5 half-lives whichever is earlier, prior to the first dose
  • Adequate hepatic function
  • Adequate renal function
  • Normal coagulation panel
  • Willingness to use effective

Key Exclusion Criteria:

  • Gastrointestinal disease
  • Significant renal disease
  • Significant cardiovascular disease
  • Significant abnormalities
  • Ongoing systemic bacterial, fungal, or viral infection (requiring antimicrobial therapy)
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    OP-1250 Phase I Part A (Dose Escalation)

    Phase I Part A will evaluate the safety and pharmacokinetics (PK)of a range of OP-1250 doses to identify the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

    Drug: OP-1250

  • Experimental
    OP-1250 Phase I Part B (Dose Expansion)

    Phase I Part B will evaluate the safety and PK of OP-1250 to confirm the RP2D dose.

    Drug: OP-1250

  • Experimental
    OP-1250 Phase II

    This portion of the study further explores the clinical activity, safety, and PK of OP-1250 monotherapy at the RP2D and will estimate preliminary anti-tumor efficacy in 3 cohorts. Cohort A will enroll subjects with measurable disease without evidence of Central Nervous System (CNS) metastases; Cohort B will enroll subjects with non-measurable (evaluable) disease without evidence of CNS metastases; and Cohort C will enroll subjects with evaluable disease (measurable and non-measurable) with CNS metastases.

    Drug: OP-1250

Interventions

  • Complete Estrogen Receptor ANtagonist (CERAN)

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)

    Number of Participants with Dose Limiting Toxicities (DLT) during Dose Escalation Only

    Time frame: Up to 28 days from start of treatment

  2. Characterize the Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) of OP-1250 That Had at Least One Treatment Emergent Adverse Event

    Characterize the incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of OP-1250 in patients that had at least one treatment emergent adverse event according to NCI-CTCAE version 5.0.

    Time frame: Up to 3 years, 11 months, and 17 days.

  3. Pharmacokinetics of OP-1250

    Plasma concentrations of OP-1250 assessed steady state

    Time frame: AUC (0-24) at steady state after 4 weeks of administration

  4. Anti-tumor Activity of OP-1250 (cPR)

    Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines (Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR)). Overall response rate which includes confirmed Partial Response (cPR).

    Time frame: Imaging studies performed every 8 weeks from date of first dose through cycle 9 then afterwards every 12 weeks until date of first documented disease progression: assessed up to 3 years, 11 months, and 17 days

07

Results

Posted May 11, 2026

Participant flow

Participant flow — Overall Study
Milestone30 mg QD (Phase 1a)60 mg QD (Phase 1a)60 mg (Phase 1b)90 mg QD (Phase 1a)120 mg QD (Phase 1a)120 mg QD (Phase 1b)120 mg QD (Phase 2)150 mg QD (Phase 1a)210 mg QD (Phase 1a)300 mg QD (Phase 1a)120 mg QD (Phase 2COHORT C ONLY)
Started56276629485777
Completed56266629465777
Not completed00100020000
Withdrew: Patient remained on study treatment in an extension of the protocol00100020000

Outcome measures

PrimaryDose Limiting Toxicities (DLT)

Number of Participants with Dose Limiting Toxicities (DLT) during Dose Escalation Only

Time frame:
Up to 28 days from start of treatment
Reported as:
Count of participants · Participants
Dose Limiting Toxicities (DLT)
Participants30 mg QD (Phase 1a)60 mg QD (Phase 1a)90 mg QD (Phase 1a)120 mg QD (Phase 1a)150 mg QD (Phase 1a)210 mg QD (Phase 1a)300 mg QD (Phase 1a)TOTAL (Phase 1a)60 mg QD (Phase 1b)120 mg QD (Phase1b)Cohort A (Phase 2)Cohort B (Phase 2)Cohort C (Phase 2)
Dose Limiting Toxicities (DLT)0000000000000
PrimaryCharacterize the Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) of OP-1250 That Had at Least One Treatment Emergent Adverse Event

Characterize the incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of OP-1250 in patients that had at least one treatment emergent adverse event according to NCI-CTCAE version 5.0.

Time frame:
Up to 3 years, 11 months, and 17 days.
Reported as:
Count of participants · Participants
Characterize the Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) of OP-1250 That Had at Least One Treatment Emergent Adverse Event
Participants30 mg QD60 mg QD90 mg QD120 mg QD150 mg QD210 mg QD300 mg QD120 mg QD (COHORT C ONLY)
Characterize the Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) of OP-1250 That Had at Least One Treatment Emergent Adverse Event5295795776
PrimaryPharmacokinetics of OP-1250

Plasma concentrations of OP-1250 assessed steady state

Time frame:
AUC (0-24) at steady state after 4 weeks of administration
Reported as:
Geometric mean · ng/mL*h
Pharmacokinetics of OP-1250
ng/mL*h30mg QD60mg QD90mg QD120mg QD150mg QD210mg QD300mg QD
Pharmacokinetics of OP-12501956 ± 33.04014 ± 46.27668 ± 82.49163 ± 38.112580 ± 27.322439 ± 47.225438 ± 40.2
PrimaryAnti-tumor Activity of OP-1250 (cPR)

Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines (Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR)). Overall response rate which includes confirmed Partial Response (cPR).

Time frame:
Imaging studies performed every 8 weeks from date of first dose through cycle 9 then afterwards every 12 weeks until date of first documented disease progression: assessed up to 3 years, 11 months, and 17 days
Reported as:
Count of participants · Participants
Anti-tumor Activity of OP-1250 (cPR)
Participants30mg QD60mg QD90mg QD120mg QD150mg QD210mg QD300mg QD120 mg QD (COHORT C ONLY)
Anti-tumor Activity of OP-1250 (cPR)02040000

Adverse events

Collected over From date of first dose until 30 days post treatment discontinuation for any cause, assessed up to 3 years, 11 months, and 17 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
30 mg QD1/5 (20%)0/5 (0%)5/5 (100%)
60 mg QD5/33 (15.2%)4/33 (12.1%)29/33 (87.9%)
90 mg QD1/6 (16.7%)2/6 (33.3%)5/6 (83.3%)
120 mg QD5/83 (6%)16/83 (19.3%)79/83 (95.2%)
150 mg QD1/5 (20%)2/5 (40%)5/5 (100%)
210 mg QD1/7 (14.3%)2/7 (28.6%)7/7 (100%)
300 mg QD1/7 (14.3%)2/7 (28.6%)7/7 (100%)
120 mg QD (COHORT C ONLY)2/7 (28.6%)4/7 (57.1%)6/7 (85.7%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
Event30 mg QD60 mg QD90 mg QD120 mg QD150 mg QD210 mg QD300 mg QD120 mg QD (COHORT C ONLY)
FallInjury, poisoning and procedural complications0/50/330/60/830/50/70/72/7
BronchitisInfections and infestations0/50/330/60/831/50/70/70/7
Febrile neutropeniaBlood and lymphatic system disorders0/50/330/62/831/50/71/71/7
COVID-19Infections and infestations0/51/331/60/830/50/70/70/7
Bone painMusculoskeletal and connective tissue disorders0/50/331/60/830/51/70/70/7
BacteraemiaInfections and infestations0/50/330/60/830/50/70/71/7
Urinary tract infectionInfections and infestations0/50/330/60/830/50/70/71/7
HaematemesisInfections and infestations0/50/330/60/830/50/70/71/7
NeutropeniaBlood and lymphatic system disorders0/50/330/60/830/50/70/71/7
Disease progressionGeneral disorders0/50/330/60/830/50/71/70/7
Most frequent other events
Showing 10 of 142
Most frequent other events
Event30 mg QD60 mg QD90 mg QD120 mg QD150 mg QD210 mg QD300 mg QD120 mg QD (COHORT C ONLY)
NauseaGastrointestinal disorders2/514/332/655/834/54/76/73/7
VomitingGastrointestinal disorders1/55/331/624/832/51/75/70/7
ConstipationGastrointestinal disorders2/56/331/616/830/54/73/73/7
FatigueGeneral disorders2/513/330/624/831/52/74/72/7
HeadacheNervous system disorders1/57/331/618/831/50/74/70/7
DyspnoeaRespiratory, thoracic and mediastinal disorders0/55/331/67/831/50/73/70/7
Decreased appetiteMetabolism and nutrition disorders1/52/331/67/831/53/73/70/7
HypokalaemiaMetabolism and nutrition disorders0/50/330/60/830/50/71/73/7
PhotopsiaEye disorders0/50/332/65/830/50/73/70/7
DiarrhoeaGastrointestinal disorders2/56/330/614/831/50/71/71/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)30 mg QD (Phase 1a)60 mg QD (Phase 1a)60 mg (Phase 1b)90 mg QD (Phase 1a)120 mg QD (Phase 1a)120 mg QD (Phase 1b)120 mg QD (Phase 2)150 mg QD (Phase 1a)210 mg QD (Phase 1a)300 mg QD (Phase 1a)120 mg QD (Phase 2 COHORT C ONLY)Total
<=18 years000000000000
Between 18 and 65 years3318641733134799
>=65 years239021215443054
Age, Continuous
Age, Continuous(years)30 mg QD (Phase 1a)60 mg QD (Phase 1a)60 mg (Phase 1b)90 mg QD (Phase 1a)120 mg QD (Phase 1a)120 mg QD (Phase 1b)120 mg QD (Phase 2)150 mg QD (Phase 1a)210 mg QD (Phase 1a)300 mg QD (Phase 1a)120 mg QD (Phase 2 COHORT C ONLY)Total
Median63 (54 to 71)65 (34 to 79)60 (30 to 81)57 (40 to 58)62.5 (40 to 67)61 (39 to 77)62 (32 to 85)76 (40 to 85)65 (57 to 77)64 (37 to 82)49 (46 to 64)61 (53 to 68)
Sex: Female, Male
Sex: Female, Male(Participants)30 mg QD (Phase 1a)60 mg QD (Phase 1a)60 mg (Phase 1b)90 mg QD (Phase 1a)120 mg QD (Phase 1a)120 mg QD (Phase 1b)120 mg QD (Phase 2)150 mg QD (Phase 1a)210 mg QD (Phase 1a)300 mg QD (Phase 1a)120 mg QD (Phase 2 COHORT C ONLY)Total
Female56276629485677152
Male000000001001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)30 mg QD (Phase 1a)60 mg QD (Phase 1a)60 mg (Phase 1b)90 mg QD (Phase 1a)120 mg QD (Phase 1a)120 mg QD (Phase 1b)120 mg QD (Phase 2)150 mg QD (Phase 1a)210 mg QD (Phase 1a)300 mg QD (Phase 1a)120 mg QD (Phase 2 COHORT C ONLY)Total
American Indian or Alaska Native000000000000
Asian002000300005
Native Hawaiian or Other Pacific Islander000000000000
Black or African American001013300008
White55204524395767127
More than one race000000000000
Unknown or Not Reported0142023001013
Region of Enrollment
Region of Enrollment(participants)30 mg QD (Phase 1a)60 mg QD (Phase 1a)60 mg (Phase 1b)90 mg QD (Phase 1a)120 mg QD (Phase 1a)120 mg QD (Phase 1b)120 mg QD (Phase 2)150 mg QD (Phase 1a)210 mg QD (Phase 1a)300 mg QD (Phase 1a)120 mg QD (Phase 2 COHORT C ONLY)Total
United States56204623465775134
Australia0072062000219
08

Study locations

19 sites
  • UCLA Hematology/Oncology
    Los Angeles, California 90404, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • University of Miami, Sylvester Comprehensive Cancer Center
    Deerfield Beach, Florida 33442, United States
  • Advent Health
    Orlando, Florida 32804, United States
  • Florida Cancer Center
    Sarasota, Florida 34232, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
    Indianapolis, Indiana 46202, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Cleveland Clinic Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • OHSU Knight Cancer Institute
    Portland, Oregon 97239, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Macquarie University
    Sydney, New South Wales 2109, Australia
  • Westmead
    Westmead, New South Wales 2145, Australia
  • ICON Cancer Centre
    Auchenflower, Queensland 4066, Australia
  • Cancer Research South Australia
    Adelaide, South Australia 5000, Australia
09

References and documents

Publications

  • Hamilton EP, Patel MR, Borges VF, Meisel JL, Okera M, Alemany CA, Pluard TJ, Wesolowski R, Sabanathan D, Miller KD, Conlin AK, McCarthy N, Shaw M, Tonda M, Shilkrut M, Lin NU. Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results. Breast Cancer Res. 2025 Jul 1;27(1):119. doi: 10.1186/s13058-025-02049-y. PubMed 40598566 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jul 2024, 47 months.

Results were first posted in May 2026, 1 year 9 months after primary completion. A results delay was requested in Jul 2025.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 47 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2020
First posted
Aug 10, 2020
StartActual
Aug 13, 2020
Primary completionActual
Jul 30, 2024
CompletionActual
Jul 30, 2024
Results delay requested
Jul 30, 2025
Results first posted
May 11, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04505826
Lead sponsor
Olema Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2020
Start date
Aug 13, 2020
Primary completion
Jul 30, 2024
Completion
Jul 30, 2024
Results posted
May 11, 2026
Last update
May 11, 2026

Study contacts

Margaret Tonda
study director · Olema Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palazestrant

Start the discussion